甲状腺癌复发与BRAF基因突变的关系研究

Research on Correlation between the Recurrence of Thyroid Cancer and BRAF Gene Mutation

目的探讨BRAF基因突变与甲状腺癌复发之间的关系。方法方便选择2014年4月—2015年4月期间该院收治的复发性甲状腺乳头状癌患者22例(复发组)的复发灶和原发灶标本为研究对象,再选择同期收治的无复发生存的甲状腺癌患者21例为对照组,分别对两组的BRAF基因进行测序,对T1799A位点的V600E突变情况进行观察。结果复发组中复发病灶与原发病灶BRAF基因T1799A位点V600E突变率分别为50.00%(11/22)、60.00%(12/20),其中1例患者的复发灶BRAF基因为野生型,而原发灶为突变型;同时,对照组的BRAF基因1799A位点V600E突变率为22.73%(5/22);两组的BRAF突变率比较差异有统计学意义(P<0.05)。结论甲状腺癌复发与BRAF基因突变有关,BRAF基因突变患者术后更容易出现复发,并且原发灶基因表型与复发灶不一致。

Objective To discuss the correlation between the recurrence of thyroid cancer and BRAF gene mutation. Methods The recurrence lesions and primary lesions specimens of 22 cases with papillary thyroid carcinoma admitted and treated in our hospital from April 2014 to April 2015 were selected and 21 cases of patients with thyroid carcinoma without recurrence admitted and treated in our hospital at the same period were selected as the control group, and the BRAF gene was sequenced, and V600 E mutation at T1799 A was observed. Results The V600 E mutation rate at T1799 A locus of recurrent lesions and primary lesions BRAF in the recurrence group was respectively 50.00%（11/22）and 60.00%（12/20）, and the recurrent lesion of BRAF gene of 1 case was wild type, but the primary lesion was mutation, at the same time, the V600 E mutation rate at 1799 A locus in the control group was 22.73%（5/22）, and the difference in the BRAF mutation rate between the two groups was statistically significant（P〈0.05）. Conclusion The recurrence of thyroid cancer is related to the BRAF gene mutation, and the patients with BRAF gene mutation are easy to reoccur, and the gene phenotypes of primary lesions are not consistent with recurrent lesions.